Targeted and Immune Cancer Therapy

This cost-effectiveness analysis compares nivolumab plus ipilimumab vs sunitinib to examine whether the drug combination is cost-effective from a US payer perspective as a first-line treatment for intermediate- and poor-risk patients with metastatic renal cell carcinoma.

This systematic review examines the association of immune checkpoint inhibitor therapy with immune-related adverse effects, antitumor activity, and viral load in patients with HIV infection and advanced-stage cancer.

An HIV-positive man in his 30s being treated with pembrolizumab for metastatic programmed cell death ligand 1–positive squamous non–small cell lung cancer presents with pruritic, mildly painful, hyperpigmented papules and plaques on both feet. What is your diagnosis?

This study assesses whether plasma-based next-generation sequencing was associated with improved mutation detection and enhanced delivery of personalized therapy in a real-world clinical setting of patients with non–small cell lung cancer.

This follow-up of a randomized phase 3 trial compares the 3-year survival with nivolumab vs that with dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma.

This phase 2 randomized clinical trial compare the efficacy and toxicity profiles of durvalumab monotherapy and tremelimumab monotherapy against a combination of both in patients with recurrent or metastatic head and neck squamous cell carcinoma with low or no expression of programmed death ligand 1.

This Viewpoint discusses the initials results of the NCI-MATCH trial, a phase 2 study that seeks to determine whether targeted therapies for specific gene mutations will lead to objective responses agnostic to the primary cancer type.

A 41-year-old woman with stage IIa melanoma of the upper thigh presented with diffuse erythematous induration of the upper thigh expanding to the lower left abdominal area and palpable subcutaneous nodules on the ipsilateral gluteal region and leg during nivolumab therapy. What is your diagnosis?

This phase 1b open-label study assesses the efficacy and safety of avelumab, an anti–programmed death ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer.

This phase 1b clinical trial assesses the safety and efficacy of avelumab treatment in a multinational cohort of patients with unresectable, previously treated malignant mesothelioma.

This systematic review and meta-analysis examine randomized clinical trials to assess whether immunotherapy treatments for advanced cancer are less effective in female patients.